Dynavax Technologies Corporation (LON:0IDA)
London · Delayed Price · Currency is GBP · Price in USD 9.44
-0.16 (-1.72%)
At close: Sep 12, 2025
Dynavax Technologies Employees
Dynavax Technologies had 405 employees as of December 31, 2024. The number of employees decreased by 3 or -0.74% compared to the previous year.
Employees
405
Change (1Y)
-3
Growth (1Y)
-0.74%
Revenue / Employee
569.99K GBP
Profits / Employee
-95.04K GBP
Market Cap
833.50M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 405 | -3 | -0.74% |
| Dec 31, 2023 | 408 | 57 | 16.24% |
| Dec 31, 2022 | 351 | 40 | 12.86% |
| Dec 31, 2021 | 311 | 66 | 26.94% |
| Dec 31, 2020 | 245 | 14 | 6.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
Dynavax Technologies News
- 21 days ago - Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire
- 27 days ago - Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study - Benzinga
- 27 days ago - Dynavax says shingles shot performed on par with GSK’s Shingrix in Phase 1/2 trial - Seeking Alpha
- 27 days ago - Dynavax's shingles vaccine shows similar immune response to GSK's shot in study - Reuters
- 27 days ago - Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile - PRNewsWire
- 5 weeks ago - Dynavax Technologies: A Dip To Accumulate - Seeking Alpha
- 5 weeks ago - Dynavax Technologies Corporation 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Dynavax raises 2025 HEPLISAV-B revenue guidance to $315M-$325M and targets 60% U.S. market share by 2030 as retail momentum grows - Seeking Alpha